ReviewJournal of advanced research2017
Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.
Review in Journal of advanced research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes.Annals of medicine · 2025Pooled it
- Herbal medicine for asymptomatic hyperuricemia: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials.Frontiers in pharmacology · 2022Pooled it
- Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.Medicine · 2019Pooled it
- The impact of uric acid on musculoskeletal diseases: clinical associations and underlying mechanisms.Frontiers in endocrinology · 2025Review
- Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review.EXCLI journal · 2025Review
- The prognostic value of admission serum uric acid for acute kidney injury: a two-center retrospective analysis.Frontiers in molecular biosciences · 2025Article
- Kidney function, uric acid, and risk of atrial fibrillation: experience from the AMORIS cohort.BMC cardiovascular disorders · 2024Article
- Article
- A Drug Safety Briefing (II) in Transplantation from Real-World Individual Pharmacotherapy Management to Prevent Patient and Graft from Polypharmacy Risks at the Very Earliest Stage.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk.Healthcare (Basel, Switzerland) · 2023Article
- Underdiagnosed CKD in Geriatric Trauma Patients and Potent Prevention of Renal Impairment from Polypharmacy Risks through Individual Pharmacotherapy Management (IPM-III).Journal of clinical medicine · 2023Article
- Sex distinctive patterns in the association between serum bicarbonate and uric acid levels among healthy adults. Qatar biobank data.Frontiers in medicine · 2023Article
- Prevalence and Predictors of Renal Disease in a National Representative Sample of the Romanian Adult Population: Data from the SEPHAR IV Survey.Diagnostics (Basel, Switzerland) · 2022Article
- Urate-lowering therapy for patients with gout on hemodialysis.International journal of rheumatic diseases · 2022Article
- Research Progress on the Relationship between Dietary Patterns and Hyperuricemia.Applied bionics and biomechanics · 2022Article
- A simple prediction model of hyperuricemia for use in a rural setting.Scientific reports · 2021Article
- Alteration of normal level of serum urate may contribute to decrease in estimated glomerular filtration rate decline in healthy Japanese men.Renal failure · 2021Article
- Impact ofNutrients · 2021Article
- The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3-5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. Therefore, before adequately powered randomised, placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.